In our study, however, 6 out of 25 (24%) tumors presented with biallelic B2M mutations (4 colorectal, 2 gastric cancers, Table 1), demonstrating that B2M mutations can also occur in stage IV MSI GI cancers. The gene discussed is B2M; the disease is gastric cancer.